基于器官运动的稳健优化在乳腺癌及内乳链放疗VMAT计划中的评估
本回顾性研究纳入5例需区域淋巴结放疗(含内乳链)的左乳腺癌患者,比较基于器官运动稳健优化与非稳健优化的VMAT计划在67次CBCT上的递送剂量估计。稳健计划在乳腺CTV覆盖上显著优于非稳健计划,D98%>95%达成率92%对71%(p<0.01),且未显著增加危及器官剂量。
要点
- 稳健优化VMAT在计划CT上可生成临床可接受计划,危及器官剂量与非稳健计划无显著差异。
- 基于CBCT递送剂量估计,稳健计划乳腺CTV D98%>95%达成率92%对非稳健71%(p<0.01)。
- 稳健计划浅表乳腺覆盖可接受率94%对非稳健55%,可能减少反应性自适应再计划。
核心结论
- 基于器官运动的稳健优化VMAT能为含内乳链的区域乳腺放疗生成临床可接受的危及器官保护计划,且对分次间变化稳健,因此降低反应性自适应再计划的可能性。
研究设计与样本
- 回顾性研究,纳入5例需含内乳链区域放疗的左乳腺癌患者,比较计划CT名义场景下生成的非稳健计划与基于模拟最差场景形状变化优化的稳健计划,并在67次放疗前CBCT上重新计算递送剂量。
主要发现
- 在计划CT名义场景下,稳健优化能生成临床可接受计划,稳健与非稳健技术的危及器官剂量无显著差异。
- 所有计划(稳健与非稳健)均达到强制性靶区覆盖要求。
- 递送剂量估计显示稳健计划较非稳健计划显著改善乳腺靶区覆盖:乳腺CTV的D98%>95%临床目标达成率稳健计划92% vs 非稳健计划71%(p<0.01)。
- 稳健计划浅表乳腺覆盖可接受率为94%,非稳健技术为55%。
关键数值与推荐
- 乳腺CTV最优临床目标为D98%>95%。
- 稳健计划92%达到乳腺CTV D98%>95%目标,非稳健计划71%(p<0.01)。
- 稳健计划94%达到浅表乳腺覆盖可接受标准,非稳健计划55%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: In patients undergoing locoregional radiotherapy (RT) for breast cancer including the internal mammary chain (IMC), VMAT has been shown to be superior to tangential-field radiotherapy in terms of target coverage and minimising dose to heart and lungs. In this study we describe and validate organ motion-based robust optimisation for generating breast and locoregional lymph node VMAT plans that are robust to inter-fractional changes. MATERIALS AND METHODS: In this retrospective study of five patients with left-sided breast cancer requiring locoregional breast radiotherapy including the IMC, non-robust plans were generated in the nominal scenario (planning-CT) and corresponding robust plans were created by optimising over a range of simulated CTs representing worst-case scenario shape changes to the breast. Both plans were re-calculated on CBCT images (n = 67) acquired prior to RT to generate estimates of delivered fractional dose. Plan robustness to inter-fractional changes was assessed in terms of the estimated target coverage and OAR dose. RESULTS: Organ motion-based robust optimisation was able to generate clinically acceptable treatment plans in the nominal scenario on the planning CT with no significant differences to OAR dose between the robust and non-robust planning techniques. All plans (robust and non-robust) achieved the mandatory target coverage requirements. Estimates of delivered dose demonstrated a significant improvement in breast target coverage for the robust plans compared to non-robust plans. For the breast CTV, 92% of the robust plans achieved the optimal D98% > 95% clinical goal as compared to 71% of the non-robust plans (p < 0.01). 94% of robust plans achieved acceptable superficial breast coverage, as compared to 55% for the non-robust technique. CONCLUSIONS: Organ motion-based robust optimisation VMAT is able to produce clinically acceptable organ-at-risk sparing plans for locoregional breast radiotherapy (including the IMC) that are robust to inter-fractional changes, therefore reducing the likelihood of reactive adaptive re-planning.
引用
- Dunlop A, Colgan R, Kirby A, et al. Evaluation of organ motion-based robust optimisation for VMAT planning for breast and internal mammary chain radiotherapy. Clin Transl Radiat Oncol. 2019. PMID: 31032432. doi:10.1016/j.ctro.2019.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。